About Bonnie Falbo

Articles by Bonnie Falbo

ASH 2023: How Do We Apply T-Cell Redirection for Myeloma? Part 1: Bispecific Antibody Therapies
Jan 04, 2024
ASH 2023: Dynamic Frailty Status Could Provide Better Prediction of Survival Probability
Dec 13, 2023
ASH 2023: The Next Frontier in CAR T-Cell Therapy- GPRC5D: Auto & Allo in the Spotlight
Dec 10, 2023
$CAR T vs. Bispecific Antibodies: How's a Relapsed/Refractory Myeloma Patient to Choose? image$

CAR T vs. Bispecific Antibodies: How's a Relapsed/Refractory Myeloma Patient to Choose?
Jul 29, 2021
$ASCO 2021: FDA grants Breakthrough Therapy Designation to Teclistamab, a Bispecific Antibody for Relapsed or Refractory Multiple Myeloma image$

ASCO 2021: FDA grants Breakthrough Therapy Designation to Teclistamab, a Bispecific Antibody for Relapsed or Refractory Multiple Myeloma
Jun 06, 2021
ASCO 2020: KRD vs. VRD for Newly Diagnosed Multiple Myeloma
Jun 01, 2020
ASH 2019: Thank you Daratumumab: The Era of Four Drug Upfront Therapy for Newly Diagnosed Patients Has Arrived
Dec 17, 2019
ASH 2019: The Bone Marrow Microenvironment Moves to the Forefront
Dec 09, 2019
ASH 2019: The Debate Heats Up Over Treating High Risk Smoldering Multiple Myeloma
Dec 06, 2019
Cuándo y cómo tratar el mieloma múltiple latente
Sep 28, 2019
When and How to Treat Smoldering Multiple Myeloma
Aug 21, 2019
Myeloma Patients, Partnership and Education
Aug 13, 2019